ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Fine Chemicals Deals Flourish

by Ann M. Thayer
October 28, 2013 | APPEARED IN VOLUME 91, ISSUE 43

CPhI, the annual pharmaceutical chemicals trade show, held last week in Frankfurt, brought out the usual selection of companies looking for customers and partners. Northern Ireland’s Almac announced a partnership with Novozymes to conjugate albumin-based proteins to peptides and small-molecule drugs to improve therapeutic half-life and targeting. The collaboration combines Novozymes’s Recombumin Flex technology with Almac’s protein conjugation capabilities. SAFC, the custom manufacturing arm of Sigma-Aldrich, has joined with catalysis developer CatSci, a 2010 AstraZeneca spin-off, to increase access to synthesis technologies. Meanwhile, Paris-based Axyntis has joined with Fuji Silysia Chemical, a Japanese silica chemistry specialist, to acquire Kyralia, a French chromatography services firm. To be renamed Kyrapharm, the operation will move to Axyntis’s site in Pithiviers, France. Separately, Albemarle said it will open a kilogram-scale lab at its pharmaceutical chemicals facility in South Haven, Mich., early next year. The lab will allow Albemarle to handle customer projects from clinical development through commercial production.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment